The human immunoglobulin (pH4) for intravenous injection market is expected to witness a surge in the near future. This is primarily attributed to the ongoing COVID-19 pandemic, which has led to an increased demand for potential therapeutic options. Human immunoglobulin (pH4) is being explored as a treatment option for severe COVID-19 cases due to its ability to boost the immune response...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian